Orris

CRP test

Reading File
Searching the Web

CRP test C-reactive protein clinical uses reference range 2025

Finding Sources
Searching Images

CRP C-reactive protein inflammation acute phase response diagram

This pathophysiology diagram illustrates the conformational changes of C-reactive protein (CRP) and their divergent biological roles in the inflammatory response. The diagram depicts three distinct isomers: native pentameric CRP (pCRP), a partially dissociated pentamer (pCRP*), and monomeric CRP (mCRP). Circulating pCRP, shown as a yellow disc-shaped pentamer, is associated with 'Host defense' mechanisms, including increased phagocytosis and decreased platelet and PMN activation. Under conditions of acidosis or upon binding to activated/damaged cell membranes or microvesicles, pCRP undergoes structural transformation. The transition from membrane-bound pCRP to pCRP* and finally to individual mCRP subunits is shown along the bottom. These conformationally-altered forms (pCRP* and mCRP) are linked to 'Excessive inflammation / Tissue damage,' characterized by increased pro-inflammatory cytokine release (IL-8, IL-6, IL-1b), PMN-platelet adhesion, NETosis, thrombus formation, and endothelial dysfunction. The graphic emphasizes how the local microenvironment modulates CRP's function from a protective, anti-inflammatory circulating protein to a potent pro-inflammatory tissue-bound mediator.

This pathophysiology diagram illustrates the conformational changes of C-reactive protein (CRP) and their divergent biological roles in the inflammatory response. The diagram depicts three distinct isomers: native pentameric CRP (pCRP), a partially dissociated pentamer (pCRP*), and monomeric CRP (mCRP). Circulating pCRP, shown as a yellow disc-shaped pentamer, is associated with 'Host defense' mechanisms, including increased phagocytosis and decreased platelet and PMN activation. Under conditions of acidosis or upon binding to activated/damaged cell membranes or microvesicles, pCRP undergoes structural transformation. The transition from membrane-bound pCRP to pCRP* and finally to individual mCRP subunits is shown along the bottom. These conformationally-altered forms (pCRP* and mCRP) are linked to 'Excessive inflammation / Tissue damage,' characterized by increased pro-inflammatory cytokine release (IL-8, IL-6, IL-1b), PMN-platelet adhesion, NETosis, thrombus formation, and endothelial dysfunction. The graphic emphasizes how the local microenvironment modulates CRP's function from a protective, anti-inflammatory circulating protein to a potent pro-inflammatory tissue-bound mediator.

A pathophysiology flow diagram illustrating the synthesis, systemic release, and immunological functions of C-reactive protein (CRP). The pathway begins with an initial trigger, such as infection or other pathology, leading to the activation of innate immunity. The central vertical axis shows the liver as the primary site of CRP production, followed by the release of CRP (represented by a yellow pentagon) into the circulatory system. Text annotations specify that a blood concentration above 10 mg/L serves as a clinical indicator of pathology. The lower portion of the diagram branches into three distinct downstream effects: 1) Opsonization of pathogens, showing CRP bound to a green spherical target; 2) Complement activation, depicted by CRP interacting with a protein complex; and 3) Pro-inflammatory effects, specifically the activation of phagocytes (represented by a grey irregular cellular structure). This schematic summarizes CRP's role as an acute-phase reactant in human host defense and its diagnostic utility in clinical medicine.

A pathophysiology flow diagram illustrating the synthesis, systemic release, and immunological functions of C-reactive protein (CRP). The pathway begins with an initial trigger, such as infection or other pathology, leading to the activation of innate immunity. The central vertical axis shows the liver as the primary site of CRP production, followed by the release of CRP (represented by a yellow pentagon) into the circulatory system. Text annotations specify that a blood concentration above 10 mg/L serves as a clinical indicator of pathology. The lower portion of the diagram branches into three distinct downstream effects: 1) Opsonization of pathogens, showing CRP bound to a green spherical target; 2) Complement activation, depicted by CRP interacting with a protein complex; and 3) Pro-inflammatory effects, specifically the activation of phagocytes (represented by a grey irregular cellular structure). This schematic summarizes CRP's role as an acute-phase reactant in human host defense and its diagnostic utility in clinical medicine.

This composite educational graphic displays a serial progression of chest radiographs (A, B, C) and a corresponding line graph of C-reactive protein (CRP) levels (D) in a patient with Acute Respiratory Distress (ARD). Panel A shows initial bilateral diffuse pulmonary opacities and evidence of mechanical ventilation. Panel B, representing the third day of re-admission, demonstrates worsening bilateral alveolar and interstitial infiltrates with visible medical devices, including an endotracheal tube and central venous lines. Panel C, on the sixth day, reveals a slight improvement in lung aeration compared to B, though significant opacity remains. Graph D tracks the biochemical inflammatory response, showing a dramatic spike in CRP levels (reaching 333.6 mg/dL) coinciding with clinical deterioration and septic shock, followed by a decline. This clinical timeline illustrates the correlation between radiological findings of progressive lung injury and laboratory markers of systemic inflammation in critical care medicine.

This composite educational graphic displays a serial progression of chest radiographs (A, B, C) and a corresponding line graph of C-reactive protein (CRP) levels (D) in a patient with Acute Respiratory Distress (ARD). Panel A shows initial bilateral diffuse pulmonary opacities and evidence of mechanical ventilation. Panel B, representing the third day of re-admission, demonstrates worsening bilateral alveolar and interstitial infiltrates with visible medical devices, including an endotracheal tube and central venous lines. Panel C, on the sixth day, reveals a slight improvement in lung aeration compared to B, though significant opacity remains. Graph D tracks the biochemical inflammatory response, showing a dramatic spike in CRP levels (reaching 333.6 mg/dL) coinciding with clinical deterioration and septic shock, followed by a decline. This clinical timeline illustrates the correlation between radiological findings of progressive lung injury and laboratory markers of systemic inflammation in critical care medicine.

Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Now I have all the information needed for a thorough, authoritative answer.

C-Reactive Protein (CRP) Test

What Is CRP?

CRP is a pentameric acute-phase protein (~115 kDa) synthesized primarily by the liver in response to inflammation, infection, or tissue injury. It was first identified by Tillett and Francis in 1930 and named for its reaction with the C-polysaccharide antigen of Streptococcus pneumoniae capsule. In response to pro-inflammatory cytokines (IL-6, IL-1), hepatic CRP production rises within 6-12 hours and can increase 100- to 1000-fold above baseline. It falls rapidly (half-life ~19 hours) when the inflammatory stimulus resolves, making it a useful marker for both diagnosis and monitoring treatment response.
On serum protein electrophoresis, CRP migrates in the gamma region and can produce a small pseudoparaprotein band. It shows seasonal variation, with highest levels in winter.
  • Quick Compendium of Clinical Pathology, 5th ed.

Two Types of CRP Tests

FeatureStandard CRPHigh-Sensitivity CRP (hs-CRP)
Detection limit~5-10 mg/L< 0.3 mg/L
Main useAcute infection, inflammation monitoringCardiovascular risk assessment
Population screenedSymptomatic patientsApparently healthy or intermediate-risk individuals
The difference is mainly technical - hs-CRP assays use the same antibody but at higher dilution and with tighter calibration. They allow measurement within the "normal range" that standard assays cannot resolve.
  • Tietz Textbook of Laboratory Medicine, 7th ed.
  • Henry's Clinical Diagnosis and Management by Laboratory Methods

Reference Ranges

Standard CRP (reported in mg/dL by many US labs; mg/L by most others)

CRP Level (mg/dL)ClassificationPossible Causes
< 0.3NormalNormal
0.3 - 1.0Minor elevationObesity, pregnancy, depression, diabetes, sedentary lifestyle
1.0 - 10.0Moderate elevationRA, autoimmune disease, MI, pancreatitis, bronchitis
> 10.0Marked elevationBacterial/viral infection, systemic vasculitis, major trauma
> 50.0Severe elevationAcute bacterial infection (~90% of cases)
Note: 1 mg/dL = 10 mg/L. Always check units on your lab report.

hs-CRP Population Distribution (mg/L)

Population25th %ile50th %ile75th %ile95th %ile
American women0.61.53.59.1
American men0.81.53.28.6
European women0.91.73.48.8
European men0.81.63.38.6
  • Tietz Textbook of Laboratory Medicine, 7th ed., Table 36.26

hs-CRP Cardiovascular Risk Stratification (AHA/CDC)

hs-CRP (mg/L)Cardiovascular Risk
< 1.0Low
1.0 - 3.0Average
> 3.0High
If a value exceeds 10 mg/L, this likely reflects an acute illness - the test should be repeated once the patient has stabilized, and the result should not be used for cardiovascular risk assessment.

Clinical Uses

1. Infection and Inflammation

  • CRP > 50 mg/L is linked to bacterial infection in ~90% of cases.
  • Guides antibiotic decisions (especially in neonates, sepsis workup, community-acquired pneumonia).
  • Monitors treatment response - levels fall quickly when therapy is effective.
  • Useful for distinguishing bacterial vs. viral infection (bacterial causes larger rises).
  • Monitors flares in autoimmune/inflammatory diseases (RA, IBD, lupus, vasculitis).

2. Cardiovascular Risk Assessment (hs-CRP)

CRP is a strong, independent predictor of MI, stroke, peripheral arterial disease, and sudden cardiac death - even among apparently healthy individuals. In the Women's Health Study, hs-CRP was actually more predictive than LDL cholesterol. In the JUPITER trial, rosuvastatin significantly reduced events in patients with low LDL but elevated hs-CRP (> 2 mg/L).
The hs-CRP test is the only non-lipid biomarker endorsed by US multisociety guidelines (AHA/CDC/NACB) for cardiovascular risk management in primary prevention. It is recommended for:
  • Intermediate-risk patients (Framingham 10-year risk 10-20%) to help guide therapy decisions.
  • NOT recommended for universal population screening.
  • NOT useful for secondary prevention (management is aggressive regardless).
CRP does not appear to be causally related to atherosclerosis - it is an independent marker, not a driver. Statin therapy, smoking cessation, weight loss, and exercise all lower CRP levels.
  • Robbins, Cotran & Kumar Pathologic Basis of Disease
  • Tietz Textbook of Laboratory Medicine, 7th ed.

3. Post-Surgical and Critical Care Monitoring

Serial CRP measurements help detect post-operative complications (anastomotic leak, wound infection). Levels that fail to fall after surgery suggest occult infection.

4. Neonatal Sepsis

CRP is widely used as an early biomarker in neonatal sepsis, where clinical signs are subtle.

Mechanism and Biological Role

CRP binds phosphocholine on damaged cells and pathogens, activating the classical complement pathway and acting as an opsonin (promotes phagocytosis). Circulating pentameric CRP (pCRP) has host-defense roles, but when it dissociates into monomeric CRP (mCRP) at sites of tissue damage, it becomes pro-inflammatory - releasing cytokines (IL-6, IL-8, IL-1β), promoting PMN-platelet adhesion and thrombus formation.
CRP pathophysiology - host defense vs excessive inflammation
CRP synthesis and immune functions

Analytical Considerations

  • Sample: Serum or plasma. No fasting required - CRP is unaffected by food intake and shows almost no circadian variation.
  • Methods: Immunoturbidimetry, nephelometry, immunoassay; newer point-of-care devices (e.g., ProciseDx CRP Assay, FDA-approved 2022) give results in < 5 minutes.
  • Serial testing: For cardiovascular risk, take two measurements ≥ 2 weeks apart for reliability (same protocol as lipid panels).
  • Intraindividual variability: Relatively low in clinically stable patients - biological variability is comparable to serum cholesterol.
  • Interfering factors: Obesity, HRT (oral estrogen raises CRP), pregnancy, and metabolic syndrome all elevate CRP independently of disease.

CRP vs. ESR

FeatureCRPESR
Response to inflammationHours (6-12h)Days (24-48h)
Fall after recoveryRapidSlow
Influenced by age/sexMinimallySignificantly
Best useMonitoring acute changes, treatment responseChronic inflammatory conditions, myeloma
Current preferencePreferred by most guidelinesSupplementary
Studies suggest CRP is the best single marker for inflammation and the most reliable guide to therapeutic efficacy. - Henry's Clinical Diagnosis and Management by Laboratory Methods
This is a shared conversation. Sign in to Orris to start your own chat.